This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Cancer or Non Small Cell Lung Cancer
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine whether using two drugs together called vandetanib and selumetinib is effective in the treatment of cancer. The first part of this study will include patients with any solid tumour and the second part of this study will include only patients with non small cell lung cancer. The four main aims of this clinical study are to find out: - If the two drugs can be given safely to patients when given together. - The maximum dose that can be given safely to patients. - More about the potential side effects of the drugs and how they can be managed. - What happens to vandetanib and selumetinib inside the body.

Provided treatments

  • Drug: Vandetanib, Selumetinib
  • Drug: Vandetanib, Selumetinib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01586624. The sponsor of the trial is Cancer Research UK and it is looking for 61 volunteers for the current phase.
Official trial title:
A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in Combination With the Oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort).